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The essential hallmarks of cancer are intertwined with an altered cancer cell-intrinsic metabolism, either as
a consequence or as a cause. As an example, the resistance of cancer mitochondria against apoptosis-
associated permeabilization and the altered contribution of these organelles to metabolism are closely re-
lated. Similarly, the constitutive activation of signaling cascades that stimulate cell growth has a profound
impact on anabolic metabolism. Here, we review the peculiarities of tumor cell metabolism that might be
taken advantage of for cancer treatment. Specifically, we discuss the alterations in signal transduction path-
ways and/or enzymatic machineries that account for metabolic reprogramming of transformed cells.Metabolic Reprogramming to the Advantage
of Cancer Cells
The first tumor-specific alteration, altered metabolism, was dis-
covered by the Nobel Prize winner Otto Warburg in the 1920s.
The ‘‘Warburg phenomenon’’ consists of an increase in glycoly-
sis that is maintained in conditions of high oxygen tension (‘‘aer-
obic glycolysis’’) and gives rise to enhanced lactate production
(Brahimi-Horn et al., 2007; Warburg et al., 1924). In addition, or
alternatively, cancer cells use elevated amounts of glucose as
a carbon source for anabolic reactions. Although the Warburg
phenomenon is not universally applicable to all cancers (Funes
et al., 2007), enhanced glucose uptake is sufficiently prevalent
that it is taken advantage of to image cancer in clinics using
the glucose analog 2-(18F)-fluoro-2-deoxy-D-glucose (FDG) by
positron emission tomography (PET). FDG-PET combined with
computer tomography (PET/CT) has a >90% sensitivity and
specificity for the detection of metastases of most epithelial
cancers (Mankoff et al., 2007).
There are several reasons why enhanced glucose uptake for
glycolytic ATP generation or anabolic reactions constitutes an
advantage for tumor growth (Figure 1):
First, in conditions of aerobic glycolysis, cells can live in con-
ditions of fluctuating oxygen tension (due to inconstant he-
modynamics of distant blood vessels) that would be lethal
for cells that rely on oxidative phosphorylation (OXPHOS) to
generate ATP (Pouyssegur et al., 2006).
Second, cancer cells generate bicarbonic and lactic acids,
lactate being the principal end product of aerobic glycolysis.
Such acids condition their environment (Koukourakis et al.,
2006), favor tumor invasion (Swietach et al., 2007), and
suppress anticancer immune effectors (Fischer et al., 2007).
Lactate that is produced by tumor cells can be taken up by
stromal cells (via the monocarboxylate transporters MCT1
and MCT2) to regenerate pyruvate that either can be ex-
truded to refuel the cancer cell or can be used for OXPHOS
(Koukourakis et al., 2006). This arrangement generates a
microecosystem in which anaerobic components (cancer472 Cancer Cell 13, June 2008 ª2008 Elsevier Inc.cells) and aerobic components (nontransformed stromal
cells) engage in complementary metabolic pathways, thus
buffering and recycling products of anaerobic metabolism
to sustain cancer cell survival and growth.
Third, tumors can metabolize glucose through the pentose
phosphate pathway (PPP) to generate nicotinamide adenine
dinucleotide phosphate (NADPH) that ensures the cell’s anti-
oxidant defenses against a hostile microenvironment and
chemotherapeutic agents (Gatenby and Gillies, 2004). More-
over, NADPH can contribute to fatty acid synthesis. The non-
oxidative part of the PPP (in which ribose 5-phosphate, an in-
termediate of the PPP, is fueled into glycolysis) is controlled
by transketolase reactions, and the transketolase-1 isoform
(TKL1) is overexpressed in multiple cancers (Foldi et al.,
2007; Langbein et al., 2006).
Fourth, and most importantly, cancer cells use intermediates
of the glycolytic pathway for anabolic reactions (for instance,
glucose 6-phosphate for glycogen and ribose 5-phosphate
synthesis, dihydroxyacetone phosphate for triacylglyceride
and phospholipid synthesis, and pyruvate for alanine and ma-
late synthesis) (Gatenby and Gillies, 2004). The embryonic
isoform of pyruvate kinase (PK), which dephosphorylates
phosphoenolpyruvate (PEP) to pyruvate, is highly expressed
in tumors yet is absent from adult tissues except adipocytes
(Christofk et al., 2008a). Interestingly, this isoform, PKM2, os-
cillates from high (tetrameric) to low (dimeric) activity (Chris-
tofk et al., 2008a; Mazurek et al., 2005). The low-active
dimeric form of PKM2 provides the metabolic advantage
that the phosphometabolites upstream of pyruvate accumu-
late and are then available as precursors for the synthesis of
amino acids, nucleic acids, and lipids (Mazurek et al., 2005)
while lactate production is avoided. This principle of ‘‘deviat-
ing’’ (at least part of the) intermediates from the glycolytic
pathways toward anabolic reactions also applies to the me-
tabolism of glycolytically derived pyruvate. In proliferating
cancer cells, pyruvate may enter a truncated tricarboxylic
acid (TCA) cycle. The net result of this truncated TCA cycle
is that acetyl-CoA is exported from the mitochondrial matrix
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ReviewFigure 1. Metabolic Reprogramming in Cancer Cells
In normal cells, aerobic glycolysis implies the conversion of glucose via pyruvate into acetyl-CoA and its complete oxidation (through the mitochondrion-localized
tricarboxylic acid [TCA] cycle and oxidative phosphorylation) to CO2 and H2O (which generates 38 ATP molecules per molecule of glucose). In contrast, in tumor
cells, glycolysis tends to be aborted at either of two steps. First, aerobic glycolysis in tumor cells implies conversion of glucose into pyruvate (which generates only
two ATP molecules per molecule of glucose) and subsequently into the waste product lactic acid. Second, in tumor cells, acetyl-CoA tends to be introduced into
a truncated TCA cycle, with the net result that acetyl-CoA is exported into the cytosol and serves as a building block for cell growth and proliferation. In this trun-
cated TCA cycle, citrate is preferentially exported to the cytosol via the tricarboxylate transporter. Once in the cytosol, citrate is cleaved by ATP citrate lyase (ACL)
to generate oxaloacetate and acetyl-CoA. Oxaloacetate is reduced to malate, then reimported into mitochondria and reconverted to oxaloacetate in the matrix
(while generating NADH that represses the TCA cycle), and it reacts with acetyl-CoA to complete the substrate cycle. Small arrows pointing up or down indicate
cancer-associated upregulation/activation or downregulation/inhibition of enzymes, respectively. Alterations indicated in red can be caused by the activation of
HIF-1. CA9 and CA12, carbonic anhydrases 9 and 12; CPT, carnitine palmitoyltransferase; GLUT, glucose transporter; GSH, glutathione; HIF, hypoxia-inducible
factor; IDO, indoleamine 2,3-dioxygenase; HK, hexokinase; OXPHOS, oxidative phosphorylation; LAT1, L-type amino acid transporter 1; LDHA, lactate dehy-
drogenase isoform A; MCT, monocarboxylate transporter; PDH, pyruvate dehydrogenase; PDK, pyruvate dehydrogenase kinase; PFK, phosphofructokinase;
PI3K, phosphatidylinositol 3-kinase; PGM, phosphoglycerate mutase; PKM2, pyruvate kinase isoform M2; PPP, pentose phosphate pathway; SCO2, synthesis
of cytochrome c oxidase 2; TLK, transketolase; VDAC, voltage-dependent anion channel.(Figure 1) and becomes available for the synthesis of fatty
acids, cholesterol, and isoprenoids. Indeed, fatty acid syn-
thase (FASN), which synthesizes long-chain fatty acids from
acetyl-CoA, malonyl-CoA, and NADPH, is upregulated or ac-
tivated in many cancers (Wang et al., 2005). Similarly, choline
kinase (ChoK), which forms phosphorylcholine, is often over-
expressed in cancer (Glunde and Bhujwalla, 2007).
Thus, the entire metabolism (in particular glycolysis and the
TCA cycle) is reorganized to augment anabolic reactions linked
to cell growth and proliferation. However, it would be difficult
to reconcile enhanced lactate production (which would result
in a net loss of carbon that could have been used for anabolic re-
actions) with reduced PK activity (which rather would reduce py-
ruvate and hence lactate production) and a truncated TCA cycle
(which would consume pyruvate) unless the net consumption of
glucose was much higher in cancer cells than in their normal
counterparts.Mechanisms of Metabolic Reprogramming
The molecular mechanisms that underlie metabolic reprogram-
ming of cancer cells are complex (Figure 2). Primary defects in
OXPHOS have been invoked to explain the Warburg phenome-
non because tumor mitochondria are often relatively small,
lack cristae, and are deficient in the b-F1 subunit of the ATP(syn-
th)ase (Lopez-Rios et al., 2007). Mitochondrial DNA (mtDNA) mu-
tations may arise as a result of tumor progression (Brandon et al.,
2006), but some mtDNA mutations might actively contribute
to tumor progression. Thus, expression of a mutant mtDNA-
encoded NADH dehydrogenase subunit 2 (associated with
head and neck squamous carcinoma) as a nuclear, mitochon-
drion-targeted gene product concomitantly stimulates aerobic
glycolysis, reactive oxygen species (ROS) production, and tumor
growth (Zhou et al., 2007).
One of the principal mechanisms of aerobic glycolysis resides
in the activation of hypoxia-inducible factor (HIF), a transcription
factor that is activated by hypoxic stress but also by oncogenic,Cancer Cell 13, June 2008 ª2008 Elsevier Inc. 473
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ReviewFigure 2. Molecular Mechanisms of
Cancer-Specific Metabolic Reprogramming
As a result of oncogenic gain-of-function events
(pink) or the loss of tumor suppressors (green) affect-
ing the PI3K/Akt/mTOR/HIF axis and/or inactivation
of the p53 system, a stereotyped pattern of meta-
bolic changes is induced, leading to cancer-associ-
atedalterations inmetabolism.Note thatarrowscon-
necting different proteins do not necessarily indicate
direct interactions. ACL, ATP citrate lyase; AMPK,
AMP-activated kinase; CA9 and CA12, carbonic an-
hydrases 9 and 12; ChoK, choline kinase; CPT, car-
nitine palmitoyltransferase; FH, fumarate hydratase;
GLUT, glucose transporter; HIF, hypoxia-inducible
factor; HK, hexokinase; OXPHOS, oxidative phos-
phorylation; LAT1, L-type amino acid transporter 1;
LDHA, lactate dehydrogenase isoform A; MCT,
monocarboxylate transporter; mTOR, mammalian
target of rapamycin; NF, neurofibromin; PDK, pyru-
vate dehydrogenase kinase; PFK, phosphofructoki-
nase; PI3K, phosphatidylinositol 3-kinase; PIP3,
phosphatidylinositol triphosphate; PGM, phospho-
glycerate mutase; PHD, prolyl hydroxylase; PKM2,
pyruvate kinase isoform M2; SCO2, synthesis of
cytochrome c oxidase 2; SDH, succinate dehydro-
genase; TSC, tuberous sclerosis complex; VDAC,
voltage-dependent anion channel; VHL, von Hippel-
Lindau ubiquitin ligase.inflammatory, metabolic, and oxidative stress (Harris, 2002;
Semenza, 2007; Taylor and Pouyssegur, 2007). HIF-1 is a heter-
odimer composed of constitutive, stable b subunits and unstable
a subunits, which are synthesized yet degraded under normoxic
conditions due to the sequential action of oxygen-dependent
prolyl hydroxylases (PHDs) and the VHL ubiquitin ligase. HIF-1
stimulates the conversion of glucose to pyruvate and lactate
by upregulating glucose transporter (GLUT) isoform 1 (GLUT1),
hexokinase (HK1 and HK2, which catalyze the initial step of
glycolysis), and lactate dehydrogenase A (LDHA), as well as the
lactate-extruding enzyme monocarboxylate transporter 4
(MCT4) (Pouyssegur et al., 2006; Semenza, 2007).
In addition, HIF-1 decreases the conversion of pyruvate to
acetyl-CoA by pyruvate dehydrogenase (PDH). For this, HIF-1
transactivates the gene encoding PDH kinase 1 (PDK1), which
inhibits PDH (Kim et al., 2006; Papandreou et al., 2006). Ace-
tyl-CoA is normally fed to the TCA cycle, producing the electron
donors NADH and FADH2, which donate electrons to the respi-
ratory chain complexes I and II, respectively. Hence, by inhibiting
PDH, HIF-1 compromises OXPHOS. In addition, HIF-1 facilitates
the adaptation of mitochondria to hypoxia by transactivating the
cytochrome c oxidase (COX) subunit COX4-2 and LON, a prote-
ase that degrades COX4-1 (Fukuda et al., 2007). HIF-1 counter-
acts the stimulatory action of Myc on mitochondrial biogenesis,
thereby reducing mitochondrial mass (Zhang et al., 2007). In
contrast, HIF-1 cooperates with c-Myc to promote aerobic
glycolysis by induction of HK2 and PDK1 (Dang et al., 2008).
Besides by a decrease in O2 tension, HIF-1 can be induced as
a result of tumorigenic germline mutations of two enzymes of the
TCA cycle: the mitochondrial matrix protein fumarate hydratase
(FH) and the inner mitochondrial membrane protein succinate
dehydrogenase (SDH). SDH is also a functional member of
complex II of the respiratory chain. Loss-of-function mutations
of FH or of SDH subunits (SDHB, SDHC, and SDHD) induce
the accumulation of the TCA cycle intermediates fumarate or474 Cancer Cell 13, June 2008 ª2008 Elsevier Inc.succinate, which competitively inhibit the a-ketoglutarate-
dependent HIF-1a prolyl hydroxylase, the enzyme that usually
targets HIF-1a for destruction in an oxygen-dependent fashion
(Gottlieb and Tomlinson, 2005). These examples illustrate that in-
duction of HIF-1 may contribute to the metabolic and oncogenic
changes induced by primary mitochondrial dysfunctions.
Beyond the central role of HIF-1 activation, oncogenes and tu-
mor suppressor genes determine metabolic reprogramming of
cancer cells at several levels (Table 1), establishing multiple links
between tumor cell biology and tumor biochemistry. Perhaps the
most significant example of a switch from respiration to aerobic
glycolysis is provided by the inactivation of the tumor suppressor
p53, as discussed in the next section.
Hallmarks of Cancer Linked to Metabolic Change
Cancer cells differ from healthy cells due to a plethora of molec-
ular changes (Hanahan and Weinberg, 2000; Zitvogel et al.,
2006), many of which may be mechanistically linked to metabolic
reprogramming (Figure 3).
Self-Sufficiency in Growth Signals
Growth factors usually activate receptor tyrosine kinases
(RTKs), which then stimulate two key signal-transducing kinase
pathways: the Ras/Raf/MAP kinase (ERK) pathway and the
phosphatidylinositol 3-kinase (PI3K) pathway. ERK and PI3K
converge to activate mTOR for stimulating cell growth. Most
cancers harbor activating mutations of the master regulators
(K-Ras, H-Ras, N-Ras, B-Raf, the p110a PI3K subunit, and
RTKs) or their downstream effectors (such as the kinases Akt
and PDK1), or inactivating mutations in negative regulators of
these proteins (Shaw and Cantley, 2006) (Table 1). There are
multiple mechanisms through which the constitutive activation
of growth factor signals can cause cancer-associated metabolic
reprogramming.
The activation of tyrosine kinases including RTK and Scr family
kinases results in the phosphorylation of enzymes on tyrosine
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Gene Effects Disease Reference
Oncogenes
PI3K Activates Akt via PIP3; reduces
(via Akt) expression of the
b-oxidation enzyme carnitine
palmitoyltransferase 1A (CPT1A)
Ovarian and gastrointestinal
cancer
Deberardinis et al. (2006)
Akt Upregulates fatty acid synthase
(FASN); activates mTOR
complex 1
Breast and ovarian cancer Wang et al. (2005)
Her2 Increases, through activation
of PI3K, Akt, and mTOR,
expression of FASN and acetyl-
CoA carboxylase a (ACCa) at the
translational level
Mammary carcinoma Yoon et al. (2007)
Tyrosine kinases Generate phosphotyrosines that
can bind to pyruvate kinase
isoform PKM2, converting it from
a tetramer to a less active dimer
Multiple cancers Christofk et al. (2008b)
E7 from HPV16 Binds PKM2, converting it from
a tetramer to a less active dimer
Cervical carcinoma Mazurek et al. (2005)
Tumor Suppressors
p53 Required for expression of
SCO2 and hence optimal
OXPHOS; enhances the
expression of TIGAR,
a glycolysis inhibitor; reduces
the expression of the glycolytic
enzyme phosphoglyceromutase
Multiple cancers Matoba et al. (2006);
Bensaad et al. (2006);
Kondoh et al. (2005)
VHL Ubiquitin ligase required for
degradation of HIF-1a
Clear cell renal carcinoma Shaw and Cantley (2006)
TSC1 (hamartin) and
TSC2 (tuberin)
Negative regulators of Rheb
(which inhibits mTOR)
Tuberous sclerosis complex and
lymphangioleiomyomatosis
Shaw and Cantley (2006)
PTEN Negative regulator of class I PI3K Cowden syndrome and prostate
cancer
Shaw and Cantley (2006)
LKB1 Required for activation of AMPK Peutz-Jeghers syndrome and
sporadic lung adenocarcinoma
Shaw and Cantley (2006)
NF1 Negative regulator of RAS and
PI3K-Akt pathway
Neurofibromatosis Shaw and Cantley (2006)
PML Negative regulator of mTOR
complex 1
Promyelocytic leukemia and
lung cancer
Shaw and Cantley (2006)
Succinate dehydrogenase
subunits SDHB, C, and D
Accumulated succinate
competitively inhibits HIF-1a
prolyl hydroxylases (PHDs)
Paraganglioma (SDHB, C, and
D) and pheochromocytoma
(SDHB and D)
Gottlieb and Tomlinson (2005)
Fumarate hydratase (fumarase) Accumulated fumarate inhibits
PHDs
Leiomyomatosis and papillary
renal carcinoma
Gottlieb and Tomlinson (2005)residues. This indirectly modulates the activity of the cancer-
specific isoform of pyruvate kinase, PKM2, which can bind to
phosphotyrosine-containing peptides (Christofk et al., 2008b).
Upon interaction between PKM2 and such phosphotyrosine-
containing peptides, PKM2 releases its allosteric activator,
FBP. This results in the inhibition of PKM2 activity as PKM2 tran-
sits from its active tetrameric state to its inactive dimeric state
(Christofk et al., 2008b). This mechanism may contribute to the
stimulation of anabolic reaction by oncogenic tyrosine kinases.
The partial inhibition of PKM2 (which catalyzes the last step of
glycolysis, upstream of pyruvate) allows the intermediates ofglycolysis to ‘‘deviate’’ toward anabolic reactions and simulta-
neously avoids excessive pyruvate production. However,
PKM2 inhibition alone is not sufficient to account for the can-
cer-specific reprogramming, which relies on additional features
including a general increase in glycolytic flux.
Cell-autonomous overactivation of the PI3K/Akt system,
downstream of RTKs, mediates an increase in glucose and
amino acid flux through the plasma membrane that may be at-
tributable in part to the activation of HIF-1a (Pouyssegur et al.,
2006). Akt stimulates the expression of one glucose transporter
(GLUT1) and induces the translocation of another (GLUT4) to theCancer Cell 13, June 2008 ª2008 Elsevier Inc. 475
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The hypothetical links between different metabolic alterations and the seven nonmetabolic characteristics of neoplasia (circle) are depicted. Centripetal arrows
(pointing from the inside outwards) indicate how the seven hallmarks of cancer can impinge on metabolism. Centrifugal arrows (pointing from the outside inwards)
illustrate how neoplasia-associated metabolic reprogramming can contribute to the acquisition of the seven hallmarks. Ang-2, angiopoietin-2; GLUT, glucose
transporter; HIF, hypoxia-inducible factor; HK, hexokinase; OXPHOS, oxidative phosphorylation; PGM, phosphoglycerate mutase; PI3K, phosphatidylinositol
3-kinase; SCO2, synthesis of cytochrome c oxidase 2; VDAC, voltage-dependent anion channel; VEGF, vascular endothelial growth factor.plasma membrane. Akt stimulates glycolysis through the activat-
ing phosphorylation of 6-phosphofructo-2-kinase (PFK2) and
fatty acid synthesis through the phosphorylation of ATP citrate
lyase (Manning and Cantley, 2007). Through mechanisms that
are not fully elucidated, Akt stimulates the association of HK1
and HK2 with mitochondria (Pastorino et al., 2005), thus linking
residual ATP synthesis by mitochondria to the catalysis of the
first, rate-limiting step of glycolysis. In addition, PI3K causes
the transcriptional downregulation of carnitine palmitoyltransfer-
ase 1A (CPT1A) (Deberardinis et al., 2006), an enzyme located in
the outer mitochondrial membrane that esterifies long-chain
fatty acids to carnitine, thereby initiating the mitochondrial im-
port of fatty acids and channeling them to b-oxidation. One of
the net effects of PI3K activation is hence an inhibition of b-oxi-
dation, which may contribute to the ‘‘glucose addiction’’ of can-
cer cells (Deberardinis et al., 2006). PI3K activation also induces
FASN, and the activating phosphorylation of Akt and FASN
correlates in tissue microarrays (e.g., in ovarian cancer) (Wang
et al., 2005).
mTOR, a serine/threonine kinase, is activated downstream of
the constitutively activated PI3K/Akt system. mTOR enhances
cap-dependent protein translation and cell growth while inhibit-
ing catabolic reactions mediated by autophagy. Several clinical
trials are currently examining the therapeutic efficacy of mTOR
inhibitors (Faivre et al., 2006). Increased activation of the PI3K/
Akt/mTOR pathway leads to phosphorylation of 4E-BP1, an
inhibitor of the eukaryotic translation initiation factor eIF4E,476 Cancer Cell 13, June 2008 ª2008 Elsevier Inc.resulting in increased eIF4E activity and cap-dependent transla-
tion in cancers. eIF4E overexpression can be tumorigenic, and
its inhibition can suppress the growth of xenografted human
cancers (Graff et al., 2007). Conversely, mTOR is inhibited by
hypoxia, and breast cancers often overexpress 4E-BP1 and
eIF4G to increase the cap-independent translation of proangio-
genic, hypoxia, and survival mRNAs (Braunstein et al., 2007).
Hence, the contribution of cap-dependent versus cap-indepen-
dent translation to cancer growth remains to be investigated in
further detail.
Evading Apoptosis
Defective apoptosis not only is crucial for initial oncogenesis
but contributes to chemotherapy resistance. Cancer cells often
manifest resistance against mitochondrial membrane permeabi-
lization (MMP), which is one of the decisive steps of apoptosis
(Kroemer et al., 2007). One link between apoptosis inhibition
and metabolic reprogramming may be provided by the associa-
tion of HK with the voltage-dependent anion channel (VDAC). HK
has been shown to associate more tightly with the outer mito-
chondrial protein VDAC in tumor cells than in normal control cells
(Pedersen, 2007). This increased HK-VDAC interaction may be
due to the constitutive activation of Akt. Akt induces the translo-
cation of HK to the outer mitochondrial membrane where it binds
to VDAC, presumably because Akt interferes with the glycogen
synthase kinase 3 (GSK3)-mediated phosphorylation of VDAC
(Pastorino et al., 2005) or because Akt phosphorylates HK
(Miyamoto et al., 2008). When associated with VDAC, HK may
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step of glycolysis. In addition, HK can inhibit MMP, presumably
through an effect on the permeability transition pore complex
(PTPC) (which also involves VDAC). Accordingly, peptides that
competitively disrupt the VDAC-HK interaction can induce
MMP and subsequent apoptosis (Robey and Hay, 2006). On the-
oretical grounds, such VDAC-HK-dissociating agents would
have a dual effect and hence revert the hyperglycolytic state
while facilitating apoptosis induction.
Complete or partial OXPHOS defects may also induce apo-
ptosis resistance. Total inhibition of the respiratory chain can
suppress the activation of the proapoptotic Bcl-2 proteins Bax
and Bak, either of which serves as a near obligate mediator of
MMP (Tomiyama et al., 2006). Thus, severe OXPHOS defects,
as are found in some cancers, might be automatically coupled
to a blockade of MMP and hence an inhibition of apoptosis.
OXPHOS defects also reduce the capacity of certain xenobiotics
to elicit ROS generation in mitochondria, thereby abrogating
their proapoptotic activity. This latter mechanism may explain
the fact that r cells (cells that lack mitochondrial DNA and hence
OXPHOS) are resistant against a series of compounds that in-
duce apoptosis by provoking futile redox cycles in mitochondria
(Galluzzi et al., 2006; Kroemer et al., 2007). Thus, a state of de-
ficient OXPHOS might automatically compromise the intrinsic
pathway of apoptosis through a variety of distinct mechanisms.
Other links between mitochondrial alterations in cancer and
disabled apoptosis are more indirect. A hyperpolarization of
the inner mitochondrial transmembrane potential, as is fre-
quently seen in cancer cells (perhaps secondary to defects in
the F1F0 ATPase) (Galluzzi et al., 2006), can reduce the propen-
sity of PTPC opening (Zoratti and Szabo, 1995). There is also
a correlation between mitochondrial hyperpolarization and a rel-
ative deficiency in voltage-gated plasma membrane K+ channels
(Kv), enhancing cytosolic K+ to a level that exerts a tonic inhibi-
tory effect on caspases and apoptosis-inducing factor (AIF)
(Bonnet et al., 2007). Pharmacological inhibition of PDK1, which
is often overactivated in cancer, leads to reactivation of PDH and
reportedly corrects both the activity of Kv channels and mito-
chondrial hyperpolarization, thereby inducing cancer cell apo-
ptosis (Bonnet et al., 2007). Thus, PDK1 inhibitors may constitute
yet another example of dual-hit agents that simultaneously
reverse apoptosis resistance and metabolic reprogramming.
Limitless Replicative Potential
To ensure replicative potential, tumor cells often mutate or lose
senescence-inducing proteins such as p53. Loss of p53 is also
driven by Darwinian selection in a hypoxic environment, because
hypoxia-mediated activation of p53 can trigger cell death (Culm-
see and Mattson, 2005). As briefly stated above, inactivation of
p53 can directly cause the Warburg phenomenon through sev-
eral mechanisms. Thus, p53 positively regulates the expression
of the protein synthesis of cytochrome c oxidase 2 (SCO2),
which is required for assembling COX (Matoba et al., 2006).
p53 negatively regulates phosphoglycerate mutase (PGM), the
enzyme that converts 3-phosphoglycerate (3PG) to 2-phospho-
glycerate (2PG) in glycolysis (Kondoh et al., 2005). Moreover,
p53 transcriptionally activates TIGAR (TP53-induced glycolysis
and apoptosis regulator), an isoform of PFK2 that inhibits overall
phosphofructokinase activity, lowers the levels of FBP, and
hence inhibits glycolysis (because FBP is an allosteric activatorof the glycolytic enzyme 6-phosphofructo-1-kinase) while chan-
neling glucose to the PPP (Bensaad et al., 2006). At present,
there have been no systematic studies to determine through
which dominant (SCO2-, PGM-, or TIGAR-dependent?) pathway
inactivation of p53 impacts on cancer cell metabolism. Given the
major contribution of p53 to cancer cell biology, this issue
urgently awaits clarification.
Sustained Angiogenesis
Many tumors show increased expression of vascular endothelial
growth factor (VEGF) as a result of activated signaling pathways
(ERK, PI3K), an action that is amplified by hypoxia. Indeed, re-
cent work indicates that the expression of VEGF is cooperatively
induced by HIF-1 and c-Myc (Kim et al., 2007a). Another intrigu-
ing link between abnormal metabolism and cancer-mediated an-
giogenesis is provided by F1F0 ATPase. Both endothelial cells
and tumor cells express the F1F0 ATPase (normally an inner mi-
tochondrial membrane protein complex) at the cell surface,
where it may extrude protons from the cytosol to the extracellular
milieu and hence contribute to the net export of protons that is
required to maintain aerobic glycolysis. An endogenous angio-
genesis inhibitor, angiostatin, binds and inhibits surface F1F0
ATPase, causing intracellular acidification. Similarly, an antibody
targeting the b catalytic subunit of F1F0 ATPase has an angiosta-
tin-like antiangiogenic effect (Chi et al., 2007). These results hint
at the possibility of using a single agent that targets the cell-
surface F1F0 ATPase for subverting cancer-associated angio-
genesis and metabolic reprogramming.
Tissue Invasion and Metastasis
One mechanistic link between tumor metabolism and invasion/
metastasis is provided by HIF. HIF-1a activation causes the
loss of E-cadherin (Esteban et al., 2006; Pouyssegur et al.,
2006), the cadherin isoform that is required for the maintenance
of intercellular contacts within epithelia and that is lost during the
epithelium-mesenchyme transition (EMT). HIF-1a activation also
causes the expression of themet proto-oncogene and of TWIST,
both of which favor EMT (Pennacchietti et al., 2003; Yang et al.,
2008), and induces two proteins that play a cardinal role in me-
tastasis, the chemokine receptor CXCR4 (Igney and Krammer,
2002) and lysyl oxidase (LOX) (Erler et al., 2006). Thus, one single
cause, HIF-1a activation, may entail both metabolic reprogram-
ming and enhanced tissue invasion/metastasis. Accordingly,
mtDNA mutations can stimulate the metastatic potential of
cancer cells, presumably because enhanced ROS generation
by mitochondria leads to the activation of HIF-1a (Ishikawa
et al., 2008).
Aerobic glycolysis (and hence enhanced production of pro-
tons) causes acidification of the extracellular milieu due to the
action of multiple proton-extruding enzymes. The monocarbox-
ylate transporters MCT1 and MCT4 (which cotransport H+ with
monocarboxylate anions such as lactate) and the ubiquitous
Na+-H+ exchanger are activated by growth factors, oncogenic
transformation, hypoxia, and low intracellular pH (Counillon
and Pouyssegur, 2000). In addition, cancer cells may use the
surface V-type H+ ATPase and/or the surface F1F0 ATPase as
proton pumps. Tumor cells often express the exquisitely HIF-
inducible carbonic anhydrase isoforms 9 and 12 (CA9 and
CA12). CA9 and CA12 are transmembrane enzymes that hydrate
extracellular CO2, thereby generating membrane-impermeable
H+ and HCO3
. Rapid recapture of HCO3
 by anion transportersCancer Cell 13, June 2008 ª2008 Elsevier Inc. 477
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ensures maintenance of a normal intracellular pH, which in turn
is essential for cell survival (Pouyssegur et al., 2006; Swietach
et al., 2007). Extracellular acidity supports invasion and metasta-
sis, perhaps due to the pH-dependent activation of cathepsins
and metalloproteinases that degrade extracellular matrix and
basement membranes (Swietach et al., 2007). Irrespective of
these mechanistic details, it may be expected that pharmacolog-
ical inhibitors of the enzymes responsible for lactate production
and/or proton extrusion would have an antimetastatic effect, in
addition to reducing tumor growth.
Avoidance of Immunosurveillance
The metabolic microenvironment of tumor cells may inhibit the
function of antitumor immune effectors such as cytotoxic T lym-
phocytes (CTLs) and natural killer (NK) cells while attracting
inflammatory cells that participate in tumor progression.
Tumor-associated macrophages (TAMs) are often enriched in
hypoxic and tumor perinecrotic areas and constitute a negative
prognostic marker. Within TAMs, HIF-1 is essential to upregulate
glycolysis so that the cells can migrate into tumor beds (Cramer
et al., 2003). TAMs facilitate angiogenesis, promote tumor cell
migration, and exert local immunosuppressive effects (Condee-
lis and Pollard, 2006). As a result, pharmacological HIF-1 inhibi-
tion should—theoretically—reduce TAM infiltration into tumors.
Acidification of tumor beds can inhibit the activity of NK cells
(Lardner, 2001). Patients with high tumor burden have increased
serum lactate levels (Fischer et al., 2007), and lactate may exert
potent immunosuppressive effects, as seen in advanced cancer.
Thus, lactate suppresses the proliferation, cytokine production,
and cytolytic activity of CTLs. As a possible mechanism of this
immunosuppressive effect, extracellular lactate blocks the ca-
pacity of CTLs to export intracellular lactate by the monocarbox-
ylate transporter MCT1. The resulting lactate overload is incom-
patible with normal CTL functions (Fischer et al., 2007). Cancer
cells often overexpress indoleamine 2,3-dioxygenase (IDO), an
enzyme that catabolizes tryptophan (which is taken up by upre-
gulated L-type amino acid transporter 1 [LAT1]) to the kynurenine
pathway and oxidative stress. IDO overexpression has been
implicated in cancer-associated anorexia/cachexia (Munn and
Mellor, 2007), and kynurenine produced by tumor cells can kill
CTLs by apoptosis (Puccetti and Grohmann, 2007). These exam-
ples illustrate that therapeutic interventions designed to correct
abnormal tumor metabolism and, in particular, the inhibition of
proton extrusion, lactate production, or IDO might reestablish
a defective antitumor immune response.
Conclusions and Therapeutic Perspectives
As discussed above, alterations in cancer cell metabolism are in-
tricately linked to the principal hallmarks of cancer. These links
are established in several distinct scenarios. First, metabolic
reprogramming may be the consequence of nonmetabolic
oncogenic events. Thus, major oncogenic events (such as
constitutive activation of growth factor pathways, constitutive
activation of HIF-1, and inactivation of p53) may constitute the
common cause of metabolic programming and well-studied hall-
marks of cancer such as autonomous growth, resistance against
apoptosis, limitless replication, and angiogenesis (Figure 2 and
centrifugal arrows in Figure 3). Second, classical features of
cancer may be conditioned by metabolic reprogramming.478 Cancer Cell 13, June 2008 ª2008 Elsevier Inc.Thus, primary metabolic defects in OXPHOS may contribute to
apoptosis resistance, while local extracellular emanations of
the deregulated cancer cell metabolism may contribute to inva-
sion, metastasis, and immunosuppression (centripetal arrows in
Figure 3). Third, at an additional level of complexity, we must
consider coevolution of the distinct traits of malignancy. The
dual cause-effect relationship between tumor-specific meta-
bolic and nonmetabolic hallmarks is likewise conditioned by
the need of proliferating cancer cells to simultaneously subvert
multiple cell-intrinsic and cell-extrinsic tumor suppressor mech-
anisms and hence to emerge from a selection process that
forces the coevolution of all hallmarks of cancer, whether meta-
bolic or nonmetabolic.
Irrespective of these theoretical and speculative consider-
ations, the intimate relationship between cancer-associated
metabolic reprogramming and all other cardinal features has
therapeutic implications at several levels. First, therapeutic sub-
version of the nonmetabolic properties of cancer (interruption of
cell-autonomous growth signals, restoration of apoptosis, inhibi-
tion of angiogenesis, etc.) may suppress cancer-specific meta-
bolic programs and hence restore the normal state. This may ex-
plain the extraordinary performance of FDG-PET as a predictor
of therapeutic outcome (Bonnet et al., 2007). Second, inhibition
of the processes and enzymes that participate in metabolic
programming may have a dramatic effect on tumors, not only
by limiting cancer cell-specific bioenergetic flow and anabolic
reactions but also by reversing the neoplastic phenotype
and hence stopping growth, inducing apoptosis, and/or blocking
angiogenesis and invasion.
Such ‘‘dual hits’’ are exemplified by the inhibition of HIF (which
inhibits angiogenesis), reestablishment of p53 function (which
restores apoptosis and senescence), or suppression of the
PI3K/Akt/mTOR pathway (which inhibits growth), three interven-
tions that should also normalize metabolic functions (Figure 3).
Moreover, small inhibitors of enzymes that occupy a central
role both in cancer-specific metabolism and in other hallmarks
of cancer might be targeted for therapy (Table 2). For instance,
low-glucose conditions and inhibitors of glycolysis preferentially
induce apoptosis in ‘‘glucose-addicted’’ cells that carry active
oncogenes (e.g., Ras, Her2, and Akt) or lack tumor suppressors
(e.g., TSC1/2, LKB1, and p53) (Shaw, 2006). The HK2 inhibitor
3-bromopyruvate induces apoptosis in hepatocellular carcino-
mas in vitro and in vivo (Ko et al., 2004). This effect may involve
the inhibition of glycolysis as well as the dissociation of the anti-
apoptotic interaction between HK2 and VDAC (Kim et al.,
2007b), providing yet another example of a dual hit that has
been validated at the experimental level, in tumor-bearing
mice. Similarly, inhibition of PDK1 can restore PDH activity
(and OXPHOS) while triggering apoptosis in tumor cells in vitro
and in vivo (Bonnet et al., 2007).
The preclinical and clinical evaluation of metabolic inhibitors
for cancer therapy is in its infancy, perhaps with the notable
exception of mTOR antagonists (Faivre et al., 2006) and (unfortu-
nately rather nonspecific) activators of AMPK that are given as
oral antidiabetics and reduce the incidence of cancer (Evans
et al., 2006). The lack of enzymatic inhibitors acting at an accept-
able degree of specificity is one of the principal obstacles to
evaluating whether inhibition of bioenergetic and anabolic path-
ways, alone or in combination therapies, might finally target the
Cancer Cell
ReviewTable 2. Potential Metabolic Targets for the Treatment of Cancer
Target Desired Effects Examples of Compounds Reference
Glycolysis
Glucose uptake Inhibition of glucose transport or
of the initial steps of glycolysis
2-deoxyglucose has
radiosensitizing and
chemosensitizing effects
Simons et al. (2007)
Hexokinase (HK1 and HK2) Inhibition of enzymatic activity and
dissociation from mitochondria
3-bromopyruvate has potent
antitumor effects in vitro and in vivo
Kim et al. (2007b);
Pedersen (2007)
Pyruvate dehydrogenase
kinase 1 (PDK1)
Inhibition of PDK1 for deinhibition
of pyruvate dehydrogenase
Dichloroacetate (DCA) Bonnet et al. (2007)
Lactate dehydrogenase A (LDHA) Inhibition siRNA Fantin et al. (2006)
Pyruvate kinase (PK) isoenzyme
PKM2
Translocation of PKM2 to the
nucleus for induction of apoptosis
Somatostatin and its derivative
TT-232 (in vitro)
Stetak et al. (2007)
Fatty Acid Synthesis
ATP citrate lyase (ACL) Inhibition SB-2049990 inhibits pancreatic
cancer growth in nude mice
Hatzivassiliou et al. (2005)
Acetyl-CoA carboxylase (ACC) Inhibition Soraphen A induces apoptosis
or autophagy in vitro
Beckers et al. (2007)
Fatty acid synthase (FASN) Inhibition Cerulenin and its derivative C57
inhibit human ovarian cancer
cell growth in SCID mice
Wang et al. (2005)
Choline kinase (ChoK) Inhibition MN58b reduces
phosphomonoesters in human
cancer xenografts
Al-Saffar et al. (2006)
HIF
HIF-1a prolyl hydroxylases (PHDs) Activation of PHDs for inhibition
of HIF, achieved by reversal of
fumarate- or succinate-mediated
inhibition of PHDs
Cell-permeating a-ketoglutarate
derivatives reverse HIV activation
in SDH- or FH-deficient cells
in vitro
MacKenzie et al. (2007)
Hypoxia-inducible factor 1 (HIF-1) Inhibition of DNA binding Echinomycin (Kong et al. (2005)
Reactive oxygen species (ROS) Antioxidants neutralize ROS
and reduce HIF-1 function
via PHDs and VHL
N-acetylcysteine (NAC);
vitamin C
Gao et al. (2007)
Hypoxia Cytotoxic effects of components
that are enriched in hypoxic cells
Tirapazamine (TPZ), a hypoxia-
activated prodrug, is in clinical
evaluation for combination
chemotherapy
Brizel and Esclamado (2006)
Proton Extrusion
Na+/H+ exchanger Inhibition Cariporide Pouyssegur et al. (2006)
Bicarbonate/Cl exchanger Inhibition S3705 Pouyssegur et al. (2006)
MCT1 lactate/H+ symporter Inhibition a-cyano-4-OH-cinnamate Pouyssegur et al. (2006)
Carbonic anhydrases 9 and
12 (CA9 and CA12)
Inhibition Sulfonamide indisulam Thiry et al. (2006)
F1F0 ATP synthase Inhibition Angiostatin; antibodies Chi et al. (2007)
Other
AMPK Activation Biguanides (e.g., metformin)
and thiazolidinediones (e.g.,
troglitazone) activate AMPK
indirectly, probably through
inhibition of OXPHOS, and reduce
the risk of cancer in diabetic patients
Evans et al. (2006)
eIF4E Inhibition of translation initiation
mediated by eIF4E
Antisense oligonucleotide
inhibits growth of human
breast cancer xenografts
Graff et al. (2007)
L-type amino acid transporter 1
(LAT1)
Inhibition to reduce amino acid
transport
2-aminobicyclo (2.2.1)-heptane
2-carboxylic acid inhibits tumor
growth in a xenograft model
Nawashiro et al. (2006)Cancer Cell 13, June 2008 ª2008 Elsevier Inc. 479
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ReviewAchilles’ heel of cancer. It can be anticipated that the develop-
ment of highly specific, preferentially isoenzyme-selective meta-
bolic inhibitors will generate an entirely novel armamentarium for
our battle against cancer.
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